Citation Impact
Citing Papers
Oxidative Stress
2017 Standout
Transcriptional Regulation by Nrf2
2017 Standout
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study)
2020
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
2013
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
2020 Standout
Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression
2017 Standout
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM
2017
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
2014
Cell type-specific Nrf2 expression in multiple sclerosis lesions
2015
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
2012
Nrf2-Keap1 signaling in oxidative and reductive stress
2018 Standout
Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways
2014
On the Clinical Pharmacology of Reactive Oxygen Species
2020
Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405
2015
Macrophages in immunoregulation and therapeutics
2023 Standout
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases
2015
Psoriasis
2021 Standout
Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism
2016 Standout
Targeting immunometabolism as an anti-inflammatory strategy
2020
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
2013
Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway
2015
NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches
2018 Standout
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
2006 Standout
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane
2015
Immunopathology of multiple sclerosis
2015 Standout
Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?
2015 Standout
Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity
2018
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
2018 Standout
Dimethyl Fumarate Modulation of Immune and Antioxidant Responses: Application to HIV Therapy
2013
Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases
2015
Oxidative Stress in Cancer
2020 Standout
Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases
2018
Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology
2022 Standout
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
2019 Standout
<p>Reactive Oxygen Species: Drivers of Physiological and Pathological Processes</p>
2020 Standout
Mitochondrial TCA cycle metabolites control physiology and disease
2020 Standout
Therapies for multiple sclerosis: translational achievements and outstanding needs
2013
DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner
2015
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM
2017
Nrf2 Upregulates ATP Binding Cassette Transporter Expression and Activity at the Blood-Brain and Blood-Spinal Cord Barriers
2014
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis
2018
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
An Overview of the Advantages of KEAP1-NRF2 System Activation During Inflammatory Disease Treatment
2017
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Molecular and Chemical Regulation of the Keap1-Nrf2 Signaling Pathway
2014
Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
2014
Psoriasis Pathogenesis and Treatment
2019 Standout
Multiple Sclerosis
2018 Standout
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
2015
Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients
2017
Dimethyl fumarate for multiple sclerosis
2015
The Latest Innovations in the Drug Pipeline for Multiple Sclerosis.
2015
Dimethyl Fumarate
2013
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
2020 Standout
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
Regulated genes in psoriatic skin during treatment with fumaric acid esters
2014
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
2016
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
2015
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
2018
The NRF 2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
2018
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
2014
Oxidative Stress: A Key Modulator in Neurodegenerative Diseases
2019 Standout
Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present)
2020
Systemic Activation of NRF2 Alleviates Lethal Autoimmune Inflammation in Scurfy Mice
2017 StandoutNobel
Chemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells
2016
Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
2015 Standout
Works of Mark Novas being referenced
Safety Profile of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis (RRMS): Long-term Interim Results From the ENDORSE Extension Study (P2.200)
2014
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
2013
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience
2015
Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers
2013
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
2012
Safety, Tolerability, and Pharmacokinetics of BG-12 Administered with and without Aspirin: Key Findings from a Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Volunteers (P04.136)
2012
Efficacy and Safety of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis in the Phase 3 CONFIRM Study
2013
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
2013
Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
2012
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate
2015
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
2016
Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses From the CONFIRM Study (S41.005)
2012
Clinical and neuroimaging outcomes with BG-12 treatment in CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis), a multicenter, randomized, placebo-controlled, phase-3 study
2012